Nextar Therapeutics

Nektar Therapeutics
Public NASDAQ: NKTR
Industry Biopharmaceuticals
Founded 1990
Headquarters San Francisco, California
Products Exubera, Movantik[1]
Revenue $148.92 million (As of 2013)[2]
Website www.nektar.com

Nektar Therapeutics (Nektar) (NASDAQ: NKTR) is an American biopharmaceutical company. The company was founded in 1990 and is based in San Francisco, California.[3] The company develops new drug candidates by applying its proprietary PEGylation and advanced polymer conjugate technologies to modify chemical structure of substances.[4] It is a technology supplier to a number of pharmaceutical companies including Affymax, Amgen, Merck, Pfizer and UCB Pharma, etc.[3] The company developed the world's first inhalable non-injectable insulin, Exubera, which was awarded as the bronze award by Wall Street Journal for its technological breakthrough. Exubera was also recognized as the most innovative diabetes medicine of 2006 in Germany.[5]

Background

The company is engaged in developing a propriety pipeline of drug candidates for several therapeutic areas including oncology, pain, anti-infectives, anti-viral and immunology.[3] The company's research and development involve in small molecule and biologic drug candidates. Its drug candidate base consists of naloxegol (Movantik), a Phase III oral opioid antagonist, etirinotecan pegol, a topoisomerase inhibitor under Phase III clinical study as of 2012, NKTR 061, NKTR-181, NKTR-214, etc.[6] In 2013, the company was assignment a patent which was developed by the company and other four co-inventors.[7] The products of the company is served as a supplement to improve the pharmacokinetics, pharmacodynamics, half-life, bioavailability and other areas of drugs for the patients worldwide.[8] As of March 2014, the company had an market capitalization of $1.7 billion with an enterprise value of $1.67 billion.[2]

References

  1. ↑ Nektar Therapeutics Profile|http://finance.yahoo.com/q/pr?s=NKTR+Profile
  2. 1 2 "NKTR Key Statistics | Nektar Therapeutics Inc Stock - Yahoo! Finance". Finance.yahoo.com. Retrieved 2014-03-16.
  3. 1 2 3 "BDR: Summary for Nektar Therapeutics, Inc.- Yahoo! Finance". Finance.yahoo.com. Retrieved 2014-03-17.
  4. ↑ "Nextar Therapeutics Inc. brief introduction NASDAQ". Nasdaq.com. Retrieved 2014-03-16.
  5. ↑ "Exubera Hailed as Innovation In Prestigious European and American Awards". Prnewswire.co.uk. 2006-09-12. Retrieved 2014-03-16.
  6. ↑ "NKTR reuter.com". Reuters.com. Retrieved 2014-03-16.
  7. ↑ "Nektar Therapeutics : U.S. Patents Awarded to Inventors in Alabama (Feb. 8)". 4-traders.com. 2014-02-08. Retrieved 2014-03-16.
  8. ↑ "Nextar Marketwatch Quote Summary". Marketwatch.com. Retrieved 2014-03-16.
This article is issued from Wikipedia - version of the Thursday, May 05, 2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.